HCM
DMAAU

Heights Capital Management’s Drugs Made In America Acquisition Corp Units DMAAU Stock Holding History

Heights Capital Management’s Portfolio DMAAU Stock Details DMAAU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-650,000
Closed -$6.58M – 207
2025
Q1 		$6.58M Buy
+650,000
New +$6.56M 3.09% 7

Other funds holding DMAAU

RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
BI
Bulldog Investors Saddle Brook, New Jersey $445M AUM 2.55% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
RCM
Robinson Capital Management Grosse Pointe Farms, Michigan $239M AUM 0.62% 1-Year Est. Return
TCM
Tuttle Capital Management Riverside, Connecticut $148M AUM 64.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Heights Capital Management's DMAAU Position: Q2 2025 in Review

Heights Capital Management sold out of Drugs Made In America Acquisition Corp Units (DMAAU) in Q2 2025, closing a stake of 650,000 shares — an estimated $6.58M sold.

Heights Capital Management first reported a position in DMAAU in Q1 2025 and held it in 1 quarter. The position peaked at $6.58M in Q1 2025. 9 funds tracked by Wall St. Rank hold DMAAU as of Q2 2025.

  • Heights Capital Management reported no remaining Drugs Made In America Acquisition Corp Units position as of Q2 2025 after selling out during the quarter.
  • Heights Capital Management sold 650,000 Drugs Made In America Acquisition Corp Units shares in Q2 2025, an estimated $6.58M.
  • Heights Capital Management first reported a position in Drugs Made In America Acquisition Corp Units in Q1 2025 and held it in 1 quarter.
  • Heights Capital Management's Drugs Made In America Acquisition Corp Units position peaked at $6.58M in Q1 2025.
  • 9 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Units as of Q2 2025.

Based on Heights Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.